GARDASIL9

HPV vaccine, nonavalent (types 6, 11, 16, 18, 31, 33, 45, 52, 58) · Merck & Co.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GARDASIL9, covering 2026-03-31 to 2026-03-31. Get the full timeline:

Most recent: Clinical Trial Update: Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative Treatment for Cervical Intra-epithelial Neoplasia [Phase 3]

See pricing